Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study (PRESS)
- Study HIC#:2000022525
- Last Updated:01/01/0001
An open label, prospective, single center, pilot trial to assess feasibility and tolerability of short term blood pressure augmentation to minimize infarct progression in acute LVO stroke patients undergoing endovascular therapy.
- Age18 years and older
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact email@example.com, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of this study is to obtain preliminary data on safety and feasibility of short-term blood pressure augmentation to minimize infarct progression in acute large-vessel occlusion (LVO) stroke.
- Age is ≥18 years
- Patients presenting with anterior circulation acute ischemic stroke
- Enrollment within 24 hours of stroke onset
- Treatment with endovascular thrombectomy
- Arterial occlusion on CTA or MRA of the ICA, M1 or M2
- Mismatch - Using CT or MRI with a Tmax >6 second delay perfusion volume and either CT-rCBF or DWI infarct core volume.
- Mismatch ratio of greater than 1.8, and
- Absolute mismatch volume of greater than 15 ml, and
- Infarct core lesion volume of less than 70 mL
- Baseline SBP>200 mm Hg
- Intracranial hemorrhage (ICH) identified by CT or MRI
- Inability to access the cerebral vasculature in the opinion of the neurointerventional team
- Contraindication to imaging with MR
- A history of a left ventricular heart failure (NYHA Class ≥ III, or EF < 50%) or angina (either unstable or CCS Grade II) involving symptoms at rest or with ordinary physical activity
- Acute myocardial infarction in the past 6 months
- Signs or symptoms of acute myocardial infarction, including electrocardiogram find-ings, on admission
- Elevated serum troponin concentration on admission (>0.1 μg/L)
- Suspicion of aortic dissection on admission
- Participation in any investigational study in the previous 30 days
- Treatment with Monoamine oxidase inhibitors (MAO-I) within last 7 days